The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Canaccord Genuity on November 19, 2024. The analyst firm set a price target for $39.00 expecting RCKT to rise to within 12 months (a possible 196.35% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Canaccord Genuity, and Rocket Pharmaceuticals maintained their buy rating.

There is no last upgrade for Rocket Pharmaceuticals

There is no last downgrade for Rocket Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on November 19, 2024 so you should expect the next rating to be made available sometime around November 19, 2025.

While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $39.00 to $39.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $13.16, which is out of the analyst’s predicted range.